Embattled aesthetic devices maker Allergan (NYSE:AGN) informed California state authorities that it plans to cut 129 workers over the next few weeks.
The company, which is deeply entrenched in a battle with hostile buyers and activist investors, filed a Worker Adjustment & Retraining Notification (WARN) with the state Employment Development Dept., reporting that it would terminate the jobs by Oct. 31, 2014. The layoffs were listed as permanent.
The company has been mired for months in a high-profile battle with hostile buyer Valeant Pharmaceuticals (NYSE:VRX, TSE:VRX) and activist investor William Ackman of Pershing Square Capital Management. The unsolicited acquirers succeeded recently in forcing Allergan’s leadership to schedule a special meeting of shareholders, where Valeant and Ackman hope to oust Allergan’s board of directors.
Allergan officials did not immediately return requests for comment.
The device maker announced earlier this year that it would eliminate 13% of its global workforce, representing about 1,500 employees and 250 vacant positions in a larger restructuring effort that the company estimates could save around $475 million in the 2015 calendar year.
It’s not clear whether the recently reported cuts are part of the previously announced restructuring plan.